Table 5.
Stratification analyses of Association between the eight polymorphisms and PFS in lung cancer patients
| Genes | SNPs | Subgroups | Additive | Dominant | Recessive | |||
|---|---|---|---|---|---|---|---|---|
| OR (95%CI) | p value | OR (95%CI) | p value | OR (95%CI) | p value | |||
| MSH2 | rs4608577 | Age (>55) | 1.04 (0.22-1.86) | 0.014* | 1.10 (0.20-2.00) | 0.017* | 1.80 (-1.38-4.98) | 0.268 |
| Male | 0.86 (0.19-1.54) | 0.013* | 0.83 (0.09-1.53) | 0.028* | 2.61 (-0.08-5.31) | 0.059 | ||
| NSCLC | 1.29 (0.57-2.02) | 0.001* | 1.21 (0.42-2.00) | 0.003* | 4.45 (1.40-7.49) | 0.005* | ||
| Stage (III/IV/ED) | 0.84 (0.18-1.51) | 0.014* | 0.81 (0.09-1.54) | 0.029* | 2.51 (-0.18-5.20) | 0.068 | ||
| MSH3 | rs1650665 | SCLC | 1.82 (0.10-3.54) | 0.041* | 1.82 (0.10-3.54) | 0.041* | Ref | |
| rs26784 | SCLC | -0.95 (-1.82- -0.08) | 0.034* | -1.06 (-2.19-0.07) | 0.068 | -1.53 (-3.46-0.40) | 0.123 | |
| rs6151670 | SCLC | -0.24 (-1.18-0.70) | 0.619 | 0.17 (-0.94-1.29) | 0.761 | -2.65 (-5.14--0.16) | 0.040* | |
| rs6151914 | Age (≤55) | -1.20 (-2.19--0.21) | 0.019* | -1.32 (-2.50--0.14) | 0.030* | -2.48 (-5.55-0.59) | 0.116 | |
| NSCLC | -0.89 (-1.72--0.07) | 0.034* | -0.96 (-1.87--0.04) | 0.042* | -1.70 (-4.77-1.38) | 0.280 | ||
| MSH4 | rs3806162 | NSCLC | -0.05 (-0.61-0.51) | 0.866 | -0.32 (-0.97-0.33) | 0.336 | 1.66 (0.01-3.31) | 0.049* |
| MSH6 | rs3136329 | Male | 0.72 (0.07-1.36) | 0.030* | 0.68 (-0.06-1.43) | 0.074 | 2.10 (0.05-4.14) | 0.045* |
| Stage (II/IV/ED) | 0.32 (-0.32-0.97) | 0.326 | 0.16 (-0.59-0.91) | 0.675 | 2.08 (0.04-4.13) | 0.047* | ||
| MLH1 | rs1800734 | SCLC | 0.91 (0.10-1.72) | 0.029* | 1.33 (0.17-2.50) | 0.027* | 0.95 (-0.58-2.48) | 0.225 |
Additive model: comparison between minor allele subjects and major allele subjects. Dominant model: comparison between minor allele carriers and major homozygous subjects. Recessive model: comparison between major allele carriers and minor homozygous subjects. OR- odds ratio; CI- confidence interval; Ref.- reference. * P < 0.05.